RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia
Nature Reviews Cardiology, Published online: 23 April 2024; doi:10.1038/s41569-024-01034-wThree randomized clinical trials presented at ACC.24 demonstrate that olezarsen and plozasiran, RNA-based therapies that target APOC3, can robustly reduce plasma triglyceride levels in patients with moderate to severe hypertriglyceridaemia. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - April 23, 2024 Category: Cardiology Authors: Karina Huynh Source Type: research
Heart pump increases survival in STEMI-related cardiogenic shock
Nature Reviews Cardiology, Published online: 23 April 2024; doi:10.1038/s41569-024-01035-9Data from the DanGer Shock trial demonstrate that implantation of a microaxial flow pump in patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock increases the survival rate compared with standard care alone. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - April 23, 2024 Category: Cardiology Authors: Jennifer Harman Source Type: research
Strategies for the delivery of sex-based equity in cardiovascular clinical trials
Nature Reviews Cardiology, Published online: 23 April 2024; doi:10.1038/s41569-024-01025-xThe under-representation of women in cardiovascular clinical trials persists across participant, clinician and research roles. This gap perpetuates health inequity and hampers the generation, translation and implementation of optimal evidence-based care. Urgent action is needed to address barriers, promote diversity, and ensure inclusive trial design and health-care delivery and dissemination, for more equitable cardiovascular health. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - April 23, 2024 Category: Cardiology Authors: Julie Sanders Tim Clayton Stacey Matthews Sarah Murray Lynn Laidlaw Richard Evans Rochelle Wynne Source Type: research
Benefits of ninerafaxstat in non-obstructive hypertrophic cardiomyopathy
Nature Reviews Cardiology, Published online: 23 April 2024; doi:10.1038/s41569-024-01032-yAccording to data from the IMPROVE-HCM trial, ninerafaxstat is well tolerated by patients with symptomatic non-obstructive hypertrophic cardiomyopathy and improves exercise performance among those who are most symptomatically limited. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - April 23, 2024 Category: Cardiology Authors: Gregory B. Lim Source Type: research
No benefit of β-blockers after myocardial infarction with preserved ejection fraction
Nature Reviews Cardiology, Published online: 22 April 2024; doi:10.1038/s41569-024-01030-0In the REDUCE-AMI trial, the use of β-blockers in patients with acute myocardial infarction (MI) who have undergone early coronary angiography and have a preserved left ventricular ejection fraction did not reduce the risk of death or new MI compared with no β-blocker use. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - April 22, 2024 Category: Cardiology Authors: Gregory B. Lim Source Type: research
Self-expanding valves more beneficial than balloon-expandable valves in patients with a small aortic annulus
Nature Reviews Cardiology, Published online: 19 April 2024; doi:10.1038/s41569-024-01027-9In patients with symptomatic aortic stenosis and a small aortic annulus, a self-expanding valve has similar rates of clinical outcomes at 1 year and lower rates of bioprosthetic dysfunction compared with a balloon-expandable valve. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - April 19, 2024 Category: Cardiology Authors: Karina Huynh Source Type: research
Gut bacteria can break down cholesterol
Nature Reviews Cardiology, Published online: 16 April 2024; doi:10.1038/s41569-024-01026-wA new study identifies a group of gut bacteria that can metabolize cholesterol and are associated with lower plasma cholesterol levels. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - April 16, 2024 Category: Cardiology Authors: Irene Fern ández-Ruiz Source Type: research
Cardiovascular disease and cancer: shared risk factors and mechanisms
Nature Reviews Cardiology, Published online: 10 April 2024; doi:10.1038/s41569-024-01017-xPatients with cardiovascular disease (CVD) have an increased risk of cancer, and patients with cancer have an increased risk of CVD. In this Review, the authors discuss the shared modifiable risk factors and the shared pathophysiological mechanisms underlying the bidirectional relationship between these two prevalent diseases. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - April 10, 2024 Category: Cardiology Authors: Nicholas S. Wilcox Uri Amit Jacob B. Reibel Eva Berlin Kendyl Howell Bonnie Ky Source Type: research
Canonical and non-canonical roles of complement in atherosclerosis
Nature Reviews Cardiology, Published online: 10 April 2024; doi:10.1038/s41569-024-01016-yIn this Review, Kemper and colleagues discuss the canonical and non-canonical roles of the complement system in the pathogenesis of atherosclerosis and discuss potential new therapeutic strategies targeting the complement system for the prevention and treatment of atherosclerotic cardiovascular disease. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - April 10, 2024 Category: Cardiology Authors: Pasquale Maffia Claudio Mauro Ayden Case Claudia Kemper Source Type: research
Uncovering atherosclerotic cardiovascular disease by PET imaging
Nature Reviews Cardiology, Published online: 04 April 2024; doi:10.1038/s41569-024-01009-xIn this Review, van Leent and colleagues provide an overview of current PET imaging approaches for assessment of atherosclerotic cardiovascular disease, as well as of whole-body PET applications; discuss the link between imaging readouts and atherosclerotic plaque pathology; and highlight promising developments in PET systems and radiotracer synthesis. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - April 4, 2024 Category: Cardiology Authors: Alexander Maier Abraham J. P. Teunissen Sheqouia A. Nauta Esther Lutgens Zahi A. Fayad Mandy M. T. van Leent Source Type: research
Alain Cribier (1945–2024)
Nature Reviews Cardiology, Published online: 03 April 2024; doi:10.1038/s41569-024-01019-9Gilard and Wijns reflect on the life of Alain Cribier, who revolutionized the management of patients with valvular disease. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - April 3, 2024 Category: Cardiology Authors: Martine Gilard William Wijns Source Type: research
Interventional thrombus modification in STEMI
Nature Reviews Cardiology, Published online: 02 April 2024; doi:10.1038/s41569-024-01020-2In ST-segment elevation myocardial infarction, the role of interventional modification of thrombi in the coronary arteries before stenting is controversial. However, innovations in stroke intervention have sparked renewed interest in thrombus modification approaches. We discuss current and emerging techniques to extract or disperse thrombi, aiming to reduce downstream embolization, microvascular obstruction and myocardial injury. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - April 2, 2024 Category: Cardiology Authors: Jason L. Walsh Rafail A. Kotronias Adrian P. Banning Giovanni Luigi De Maria Source Type: research
Small extracellular vesicles from the infarcted heart can promote tumour growth
Nature Reviews Cardiology, Published online: 02 April 2024; doi:10.1038/s41569-024-01022-0After myocardial infarction, the heart secretes small extracellular vesicles with pro-neoplastic properties that can accelerate tumour growth when taken up by cancer cells. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - April 2, 2024 Category: Cardiology Authors: Karina Huynh Source Type: research
A newly identified gut hormone suppresses cholesterol production in the liver
Nature Reviews Cardiology, Published online: 28 March 2024; doi:10.1038/s41569-024-01021-1A new study identifies a hormone that is secreted by the gut in response to cholesterol absorption and can inhibit cholesterol synthesis in the liver, which prevents an increase in circulating cholesterol levels. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - March 28, 2024 Category: Cardiology Authors: Irene Fern ández-Ruiz Source Type: research
Contemporary pharmacological treatment and management of heart failure
Nature Reviews Cardiology, Published online: 26 March 2024; doi:10.1038/s41569-024-00997-0In this Review, Bozkurt provides an overview of the management of patients with heart failure across the full range of left ventricular ejection fraction, derived from the recommendations in the latest US and European guidelines. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - March 26, 2024 Category: Cardiology Authors: Biykem Bozkurt Source Type: research
